Eyenovia, Inc. (NASDAQ:EYEN – Get Free Report) major shareholder Stuart M. Grant bought 100,000 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was bought at an average cost of $0.98 per share, for a total transaction of $98,000.00. Following the acquisition, the insider now owns 5,430,715 shares of the company’s stock, valued at approximately $5,322,100.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Eyenovia Price Performance
NASDAQ EYEN remained flat at $0.99 during trading hours on Thursday. The company had a trading volume of 786,734 shares, compared to its average volume of 927,150. The business’s fifty day moving average is $1.69 and its 200 day moving average is $1.61. The stock has a market cap of $46.73 million, a P/E ratio of -1.49 and a beta of 1.72. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.17 and a quick ratio of 2.16. Eyenovia, Inc. has a 52-week low of $0.92 and a 52-week high of $5.85.
Eyenovia (NASDAQ:EYEN – Get Free Report) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17). During the same period last year, the business posted ($0.17) EPS. On average, equities analysts anticipate that Eyenovia, Inc. will post -0.91 EPS for the current year.
Hedge Funds Weigh In On Eyenovia
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Eyenovia in a research report on Tuesday, March 19th.
Read Our Latest Analysis on Eyenovia
About Eyenovia
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
Read More
- Five stocks we like better than Eyenovia
- What Are Growth Stocks and Investing in Them
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- 3 Best Fintech Stocks for a Portfolio Boost
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.